PMID- 33081551
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 48
IP  - 10
DP  - 2020 Oct
TI  - Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of 
      randomized controlled trials.
PG  - 300060520931625
LID - 10.1177/0300060520931625 [doi]
LID - 0300060520931625
AB  - PURPOSE: Our meta-analysis was undertaken to evaluate the efficacy and safety of 
      nebivolol compared with other second-generation beta blockers for hypertensive 
      patients. METHODS: We searched PubMed, the Cochrane Library, EMBASE, and Clinical 
      Trials.gov databases for randomized controlled trials (RCTs). The efficacy 
      endpoints included systolic blood pressure (SBP), diastolic blood pressure (DBP), 
      reduction of SBP and DBP, heart rate (HR), and adverse events (AEs). FINDINGS: 
      Eight RCTs with 1514 patients met the inclusion criteria. HR was significantly 
      lower in patients receiving other second-generation beta blockers compared with 
      patients receiving nebivolol. There was no difference the reduction of blood 
      pressure (SBP and DBP) or the reduction of SBP or DBP between the groups. The 
      incidence of AEs was lower in patients taking nebivolol compared with patients 
      taking other second-generation beta blockers. CONCLUSIONS: No significant difference 
      was demonstrated between nebivolol and other second-generation beta blockers in the 
      reduction of blood pressure, SBP, and DBP. The tolerability of nebivolol was 
      significantly better compared with other second-generation beta blockers, and 
      nebivolol was also associated with a stable HR and a lower risk of AEs compared 
      with other second-generation beta blockers.
FAU - Liu, Jun-Ying
AU  - Liu JY
AD  - Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, 
      China.
FAU - Guo, Li-Na
AU  - Guo LN
AD  - Department of Plastic and Cosmetic Medicine, Cangzhou Central Hospital, Cangzhou, 
      Hebei Province, China.
FAU - Peng, Wan-Zhong
AU  - Peng WZ
AD  - Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, 
      China.
FAU - Jiang, Yang
AU  - Jiang Y
AD  - Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, 
      China.
FAU - Wang, Ai-Li
AU  - Wang AL
AD  - Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, 
      China.
FAU - Guo, Xue-Min
AU  - Guo XM
AD  - Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, 
      China.
FAU - Xu, Ze-Sheng
AU  - Xu ZS
AUID- ORCID: 0000-0002-8781-6656
AD  - Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Antihypertensive Agents)
RN  - 030Y90569U (Nebivolol)
SB  - IM
MH  - *Antihypertensive Agents/adverse effects
MH  - Blood Pressure
MH  - Humans
MH  - *Hypertension/drug therapy
MH  - Nebivolol/pharmacology/therapeutic use
MH  - Randomized Controlled Trials as Topic
PMC - PMC7588777
OTO - NOTNLM
OT  - Nebivolol
OT  - adverse events
OT  - diastolic blood pressure
OT  - heart rate
OT  - hypertension
OT  - meta-analysis
OT  - systolic blood pressure
OT  - beta blocker
COIS- The authors declare that there is no conflict of interest.
EDAT- 2020/10/22 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/10/20
CRDT- 2020/10/21 05:36
PHST- 2020/10/21 05:36 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/10/20 00:00 [pmc-release]
AID - 10.1177_0300060520931625 [pii]
AID - 10.1177/0300060520931625 [doi]
PST - ppublish
SO  - J Int Med Res. 2020 Oct;48(10):300060520931625. doi: 10.1177/0300060520931625.